Cargando…
The clinical value of hematological markers in rheumatoid arthritis patients treated with tocilizumab
BACKGROUND: Emerging evidence indicates that some hematological markers have critical value in evaluating treatment response. This study was performed to determine the clinical value of hemoglobin (Hb), platelet (Plt), neutrophil‐to‐lymphocyte ratio (NLR), and platelet‐to‐lymphocyte ratio (PLR) in r...
Autores principales: | Zhou, Li, Xiao, Dong‐Mei, Qin, Wen, Xie, Bin‐Hua, Wang, Ting‐Hui, Huang, Hua, Zhao, Bao‐Jing, Han, Xi, Sun, Qing‐Qing, Wu, Xiu‐Di, Cen, Han |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595377/ https://www.ncbi.nlm.nih.gov/pubmed/30779461 http://dx.doi.org/10.1002/jcla.22862 |
Ejemplares similares
-
Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
por: Rubbert-Roth, Andrea, et al.
Publicado: (2016) -
Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab
por: Hirao, Makoto, et al.
Publicado: (2011) -
Review of tocilizumab in the treatment of rheumatoid arthritis
por: Okuda, Yasuaki
Publicado: (2008) -
Tocilizumab in the treatment of rheumatoid arthritis and beyond
por: Shetty, Anjali, et al.
Publicado: (2014) -
Tocilizumab: A Review in Rheumatoid Arthritis
por: Scott, Lesley J.
Publicado: (2017)